New guidelines on the management of anaphylaxis from the European Academy of Allergy and Clinical Immunology (EAACI) underscore the need to use intramuscular epinephrine as first-line treatment. The ...

At the American College of Allergy, Asthma & Immunology Annual Scientific Meeting, Jay A. Lieberman, MD, FACAAI, discussed upcoming changes to anaphylaxis guidelines and treatment strategies, ...

Please provide your email address to receive an email when new articles are posted on . Most anaphylactic reactions were moderate and occurred during the up-dosing phase of OIT treatment. About half ...

BOSTON (Oct. 24, 2024) – Anaphylaxis can come on suddenly and without warning, and because its symptoms can be fatal, it is scary for those who encounter it. Two new studies being presented at this ...

AllergyAware e-learning course significantly improved school personnel's anaphylaxis knowledge and confidence in using epinephrine auto-injectors. Food allergies increase anaphylaxis risk, impacting ...

Misinformation and outdated protocols contribute to the suboptimal management of anaphylaxis by patients and healthcare professionals, based on data from two new studies presented at the American ...

A study of more than 700,000 CT scans with iodinated contrast found an overall anaphylaxis incidence of 0.02%. Of these cases, 10% required three or more doses of epinephrine or initiation of IV ...

A groundbreaking consensus report on anaphylaxis – the severe reaction some people experience from bee stings, peanut butter exposures, medications, and the like – has been released by the Global ...

The new guidelines reflect the efforts of a 46-member panel of experts from 14 countries and seven medical specialties. The findings have received endorsements from 34 medical and patient advocacy ...

New guidelines help non-medics correctly identify acute allergic reactions requiring epinephrine administration ...

Characterizing and learning from medical malpractice cases against medical oncologists using a national claims database. This is an ASCO Meeting Abstract from the 2022 ASCO Quality Care Symposium.

New research based on real-world data largely aligns with the scientific literature, although one monoclonal antibody—dupilumab—stood out for its very low risk. Patients receiving monoclonal ...